BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chiang SF, Huang KC, Chen WT, Chen TW, Ke TW, Chao KSC. Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer. Cancer Immunol Immunother 2021;70:2937-50. [PMID: 33713152 DOI: 10.1007/s00262-021-02894-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Le Naour J, Sztupinszki Z, Carbonnier V, Casiraghi O, Marty V, Galluzzi L, Szallasi Z, Kroemer G, Vacchelli E. A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients. OncoImmunology 2022;11:2059878. [DOI: 10.1080/2162402x.2022.2059878] [Reference Citation Analysis]
2 Zhao Z, Wang Z, Wu Y, Liao D, Zhao B. Comprehensive analysis of TAMs marker genes in glioma for predicting prognosis and immunotherapy response. Molecular Immunology 2022;144:78-95. [DOI: 10.1016/j.molimm.2022.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chiang SF, Huang KC, Chen WT, Chen TW, Ke TW, Chao KSC. An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1). Oncoimmunology 2021;10:1926074. [PMID: 34026338 DOI: 10.1080/2162402X.2021.1926074] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]